

Antidepressant And Anxiolytic-hypnotic Exposure Prior To Hospital Admission For Acute Liver Injury

A. Grolleau¹, S. Duret¹, N. Thurin¹, M. Duong¹, R. Lassalle¹, P. Blin¹, C. Droz-Perroteau¹, SE. Gulmez¹, N. Moore¹

¹ Bordeaux PharmacoEpi, INSERM CIC1401, Université de Bordeaux, Bordeaux, France

Abstract

Background: Acute liver injury (ALI) is a major drug safety issue. Several antidepressant (AD) and anxiolytic-hypnotic (BZ) drugs have been associated with ALI. **Objectives:** To quantify exposure to AD/BZ prior to hospital admission for acute liver injury (ALI) in the French National healthcare systems database SNDS (66 million persons). Methods: All hospital admissions for ALI (K71.1,.2,.6,.9, K72.0) over 2010-2014 were identified in SNDS. Cases with specific diagnoses of liver disease/injury were excluded. Exposures of interest were BZ (ATC codes N05B, N05C) and AD (N06A) dispensed from 7 to 60 days before hospital admission to avoid indication and protopathic biases. Reference populations were a) the whole French population over the study period extrapolated from the 1/97th permanent representative sample EGB, in a case-population analysis: b) 5 controls/case from the same database matched on age and sex using the same index date for the case-control analysis. Results are provided as a) number of cases per million users (MP) or patient-years (MPY) with 95% confidence intervals [95%CI] b) Odds Ratios (OR) [95%CI] compared to non-exposure. Results: 4807 cases with hospital admission for ALI were identified matched to 24035 controls. 3619 cases and 12796 controls had been exposed to any drug within 7-60 days preadmission (OR 3.1 [2.9-3.4]). 914 cases were exposed to at least one anxiolytic BZ and 495 to at least one hypnotic (vs. 2289 and 1207 controls (OR 2.3 [2.1-2.5] and 2.2 [2.0-2.5])): ranging from 244 cases for zolpidem to 5 for estazolam. Rates of ALI was 43 [37-47] cases/ MPY for any BZ with individual drugs risk from 132 for clotiazepam [62-244] or hydroxyzine [113-153] to 32 [18-51] for loprazolam. Zolpidem was associated with 55 [47-62] cases/MPY. Per MP rate was 45 [41-51] for all BZ, ranging from clorazepate 68 [49-94] to prazepam 26 [21-33]. Zolpidem was associated with 36 [31-41] cases/MP, alprazolam 28 [24-32], bromazepam 30 [26-35]. OR ranged from 7.5 [1.2-45] for flunitrazepam to 1.5 [1.2-1.9] for lorazepam, with 2.1 [1.8-2.5] for zolpidem and 1.7 [1.5-2.0] for bromazepam. 732 cases were exposed to AD vs. 1809 controls (OR 2.3 [2.1-2.5]) from 137 for escitalopram to 5 for fluvoxamine. Event rates/MPY ranged from 115 [88-146] for mianserin to 32 [26-40] for escitalopram; per MP from 118 [38-275] (fluvoxamine) to 31 [26-37] (escitalopram). OR ranged from moclobemide 7.5 [1.2-45] or agomelatine 6.36 [2.9-14] to escitalopram 1.8 [1.5-2.2]. Conclusion: Risks associated with most BZ or AD were within the same order of magnitude within each class, with a few outliers, none unexpected.

Declaration of Interest Statement

This study was supported by an unconditional public joint help from *Direction Générale de la Santé* (DGS), from *Mission* recherche de la Direction de la Recherche, des Etudes, de l'Evaluation et des Statistiques (MiRe-DREES) of Caisse Nationale d'Assurance Maladie des Travailleurs Salariés (CNAMTS), Régime Social des Indépendants (RSI) and Caisse Nationale de Solidarité pour l'Autonomie (CNSA), as part of the general call for projects by IReSP (Appel à Projets, Institut de Recherche en Santé Publique) in 2013. It was conducted by Bordeaux PharmacoEpi Platform. All authors, none declared other relationships to disclose for this study.

Background

- > Acute Liver Injury (ALI) is a major source of drug-induced regulatory action, drug-induced hospital admissions and burden of care.
- > To our knowledge, hepatotoxicity studies were based on identification of individual cases and concerned a few hundred cases.
- > A previous field study (SALT) exhaustively explored the acute liver failure leading to liver

1. Gulmez SE, et al. Transplantation for acute liver failure in patients exposed to NSAIDs or paracetamol (acetaminophen): the multinational case-population SALT study. Drug Saf. 2013;36(2):135-44.

2. Gulmez SE, et al. Risk of hospital admission for liver injury in users of NSAIDs and nonoverdose paracetamol: Preliminary results from the EPIHAM study. Pharmacoepidemiol Drug Saf. 2018;27(11):1174-81.

transplantation in 7 countries. The EPIHAM study was conducted in order to identify drugs with less severe hepatotoxicity, still resulting in hospital admission using the French nationwide claims database.

Objectives

To quantify exposure to antidepressant (AD) and anxiolytic-hypnotic (BZ) prior to hospital admission for ALI in the French National healthcare systems database SNDS.

Methods

Study design

- Case-population study of adults with a 1st hospitalization for ALI from 2010 to 2014.
- Case-control study of adults exposed to interest drugs from 2010 to 2014.
- > Data source: the SNDS French nationwide claims database which covers 99% of the French population and the EGB 1/97th permanent representative sample of SNDS.
- Study population
- Case identified in SNDS among adult patients with a 1st hospital admission from 2010 to 2014 with main diagnosis of acute toxic liver injury (ICD-10 codes K71.1, K71.2, K71.6, K71.9) or hepatic failure (ICD-10 code K72.0) (Figure 1).
- **Reference population** identified in EGB among adult patients affiliated at least one day for each year considered to the national healthcare insurance system for salaried workers (CNAMTS), extrapolated to the whole French population.
- Control identified in EGB among adult patients affiliated to the CNAMTS and hospitalized between 2010 and 2014 for a reason other than ALI. Control were matched on age and gender using the same index date with a ratio of 5 controls / case identified (Figure 2).
- Index date: Date of first hospital admission for ALI.
- **Exposure**
 - Case: AD (ATC code N06A) and BZ (ATC codes N05B, N05C) dispensing between 7 and 60 days preceding the date of 1st hospital admission for ALI (to avoid indication and protopathic bias).
 - Reference population: number of patients with at least one interest drug dispensed over the study period (2010-2014), extrapolated to the whole French population.
 - Control: AD (ATC code N06A) and BZ (ATC codes N05B, N05C) dispensing in the same period as the identified cases.
- Data analysis
 - Incidence rate of ALI: number of exposed cases over the study period per million users (MP) or patient-years (MPY) with 95% confidence intervals (case-population analysis).
 - Risk of ALI in exposed patients (Odds Ratio OR, conditional logistic regression) compared to non-exposed patients (case-control analysis).



Identification of ALI cases – Case-population analysis

	ce population: Patients identified in SNDS with a 1 st hospitalization for ALI between 2010 and 2014					
ICD-10 codes	ICD-10 codes	ICD-10 code				
K71.1 or K71.2*	K71.6 or K71.9*	K72.0*				
n = 5 560	n = 2 566	n = 16 189				

Exclusion of patients with at least one of the following criteria:

1			
	 At least one hospitalization with a chronic disease diagnosis in the 60 days before the hospitalization of interest or during the hospitalization of interest** (ICD-10 codes: B18 - C - F10 - G31 - I50 - I81 - I85 - K70 - K74 - K76 - K80 - K83 - R18 - Z95, T86.4), n = 12 873 		
	- At least one hospitalization in the 60 days before index date with a ICD-10 code of liver transplant status* (ICD-10 code: Z94.4), n = 5		
	- Hospitalization ended in the 30 days before index date, n = 1 057		
•	 Hospitalization started in the 7 days before index date, n = 29 		
	 Previous hospitalization in rehabilitation centers ended in the 30 days before index date or with a start date within 30 days before hospitalization of interest, n = 66 		
	 Hospital stay of hospitalization of interest with endoscopies, diagnostic procedures, or HIV disease n = 105 		
	 Previous hospital stay with a code including alcoholic cirrhosis, chronic hepatitis, alcoholics or malignant neoplasm (pancreas or hepatobiliary), n = 163 		
	 Hospitalization of interest after aggregation with a poisoning diagnosis** (ICD-10 codes T36 to T50), n = 697 		
	 Hospitalization of interest after aggregation with a chronic disease diagnosis** (ICD-10 codes: B18 C - F10 - G31 - I50 - I81 - I85 - K70 - K74 - K76 - K80 - K83 - R18 - Z95, T86.4), n = 108 		
ALI cases analyzed n = 4 807			

* Main diagnosis; ** Main, associated or related diagnosis; *** Hospitalizations with a duration of 0 day or with a release "at home" were excluded from the aggregation

Figure 1. Identification procedure of ALI cases in SNDS between 2010 and 2014

Exposure of adult ALI cases

université

de **BORDEAUX**

- 19% of cases were exposed to at least one anxiolytic BZ and 10% to at least one hypnotic. Exposure ranged from 244 cases for zolpidem to 5 cases for estazolam (Table 1).
- Exposure to AD (17%) ranged from 137 cases for escitalopram to 5 cases for fluvoxamine.

Incidence of hospitalization for ALI

- For BZ, event rates per MPY ranged from 132 [62-244] for clotiazepam to 32 [18-51] for loprazolam and per MP from 68 [49-94] for potassium clorazepate to 13 [9-17] for etifoxin.
- For AD, event rates per MPY ranged from 115 [88-146] for mianserin to 32 [26-40] for escitalopram and per MP from 118 [38-275] for fluvoxamine to 31 [26-37] for escitalopram.

Identification of controls – Case-control analysis




Figure 2. Identification procedure of controls in EGB between 2010 and 2014

Risk of hospital admission for ALI

- For BZ, OR ranged from 7.5 [1.2-44.8] for flunitrazepam to 1.5 [1.2-1.9] for lorazepam, with an OR of 2.1 [1.8-2.5] for zolpidem and 1.7 [1.5-2.0] for bromazepam (Figure 3).
- For AD, OR ranged from 7.5 [1.2-44.8] for moclobemide or 6.4 [2.9-14.0] for agomelatine to 1.8 [1.5-2.2] for escitalopram. OR [CI 95%] Cases Controls

L J I		Cases	CONTROL
N05B - Anxiolytics N05BA12 - Alprazolam		914 215	2289 517
N05BA08 - Bromazepam		189	554
N05BB01 - Hydroxyzine		166	271
N05BA04 - Oxazepam		127	234
N05BA06 - Lorazepam		104	351
N05BA11 - Prazepam		75	176
N05BX03 - Etifoxine		51	120
N05BA05 - Potassium clorazepate		39	60
N05BA01 - Diazepam		36	44
N05BA09 - Clobazam		22	54
N05BA16 - Nordazepam		11	14
N05BA21 - Clotiazepam		10	31
N05BC01 - Meprobamate		9	25
N05BC51 - Meprobamate, combinations		8	27
N05BE01 - Buspirone		6	17
N05C - Hypnotics and sedatives	H	495	1207
N05CF02 - Zolpidem		244	593
NOECEO1 Zanialana		160	407

Table 1. BZ and AD exposure of adult ALI cases within 7 and 60 days preceding the index date and incidence of hospitalizations for ALI between 2010 and 2014


Drugs dispensed within 7-60 days before index date	Case n = 4 807	Case / million patients [95% Cl] ¹	Case / million patients-year [95% Cl] ¹
N05B - Anxiolytics, n (%)	914 (19.0)	41.48 [36.94 ; 46.16]	56.57 [51.10 ; 62.05]
N05BA12 - Alprazolam	215 (4.5)	27.77 [23.88 ; 32.05]	74.43 [65.70 ; 87.60]
N05BA08 - Bromazepam	189 (3.9)	29.94 [25.58; 34.77]	63.16 [54.75; 73.00]
N05BB01 - Hydroxyzine	166 (3.5)́	26.80 22.72 31.36	132.02 [113.15; 153.30]
N05BA04 - Oxazepam	127 (2.6)́	49.09 40.84 ; 58.49	54.43 [43.80 ; 65.70]
N05BA06 - Lorazepam	104 (2.2)	62.78 [51.29 ; 76.08]	43.42 [36.50 ; 51.10]
N05BA11 - Prazepam	75 (1.6)	26.47 [20.82 ; 33.18]	74.15 [58.40 ; 91.25]
N05BX03 - Etifoxine	51 (1.1)	12.69 [9.44 ; 16.68]	66.18 [47.45 ; 87.60]
N05BA05 - Potassium clorazepate	39 (0.8)	68.48 [48.69 ; 93.60]	63.17 [43.80 ; 87.60]
N05BA01 - Diazepam	36 (0.7)	29.01 [20.31 ; 40.16]	40.42 [29.20 ; 54.75]
N05BA09 - Clobazam	22 (0.5)	40.09 [25.13 ; 60.69]	68.67 [43.80 ; 102.20]
N05BA16 - Nordazepam	11 (0.2)	45.48 [22.70 ; 81.37]	72.73 [36.50 ; 131.40]
N05BA21 - Clotiazepam	10 (0.2)	17.18 [8.24 ; 31.59]	132.12 [62.05 ; 244.55]
N05BC01 - Meprobamate	9 (0.2)	26.07 [11.94 ; 49.48]	74.31 [32.85 ; 142.35]
N05BC51 - Meprobamate, combinations	8 (0.2)	24.88 [10.73 ; 49.01]	91.18 [40.15 ; 178.85]
N05BE01 - Buspirone	6 (0.1)	20.96 [7.68 ; 45.62]	81.84 [29.20 ; 178.85]
N05C - Hypnotics and sedatives, n (%)	495 (10.3)	46.55 [41.08 ; 52.30]	47.13 [40.15 ; 54.75]
N05CF02 - Zolpidem	244 (5.1)	36.19 [31.29 ; 41.54]	54.85 [47.45 ; 62.05]
N05CF01 - Zopiclone	163 (3.4)	34.55 [29.26 ; 40.47]	53.57 [43.80 ; 62.05]
N05CD06 - Lormetazepam	67 (1.4)	53.08 [41.14 ; 67.42]	36.31 [29.20 ; 47.45]
N05CD11 - Loprazolam	19 (0.4)	30.63 [18.44 ; 47.83]	31.95 [18.25 ; 51.10]
N05CX - Hypnotics and sedatives in combination (excl barbiturates)	15 (0.3)	28.71 [16.08 ; 47.36]	48.17 [25.55 ; 80.30]
N05CD04 - Estazolam	5 (0.1)	37.56 [12.17 ; 87.66]	61.18 [18.25 ; 142.35]
N06 - Psychoanaleptics, n (%)	798 (16.6)	59.35 [52.77;66.15]	41.71 [36.50 ; 47.45]
N06AB10 - Escitalopram	137 (2.9)	31.26 [26.16 ; 37.04]	32.35 [25.55 ; 40.15]
N06AB05 - Paroxetine	117 (2.4)	43.30 [35.78 ; 51.94]	43.22 [36.50 ; 51.10]
N06AX16 - Venlafaxine	99 (2.1)	53.52 [43.49 ; 65.15]	51.39 [40.15 ; 62.05]
N06AB03 - Fluoxetine	75 (1.6)	51.39 [40.42 ; 64.41]	44.41 [36.50 ; 54.75]
N06AA09 - Amitriptyline	65 (1.4)	35.08 [27.08 ; 44.72]	105.37 [80.30 ; 135.05]
N06AX03 - Mianserin	64 (1.3)	51.37 [39.56 ; 65.60]	114.81 [87.60 ; 146.00]
N06AB04 - Citalopram	51 (1.1)	46.31 [34.48; 60.90]	44.56 [32.85 ; 58.40]
N06AX21 - Duloxetine	49 (1.0)	49.19 [36.39 ; 65.03]	60.15 [43.80 ; 80.30]
N06AB06 - Sertraline	33 (0.7)	40.32 [27.75 ; 56.62]	32.99 [21.90 ; 47.45]
N06AX11 - Mirtazapine	29 (0.6)	40.16 [26.90 ; 57.68]	58.63 [40.15; 83.95]
N06AX14 - Tianeptine	28 (0.6)	40.46 [26.89 ; 58.48]	64.42 [43.80 ; 94.90]
N06AA04 - Clomipramine	26 (0.5)	63.85 [41.70; 93.54]	74.74 [47.45 ; 109.50]
N06AX22 - Agomelatine	14 (0.3)	41.23 [22.53 ; 69.17]	75.16 [40.15 ; 127.75]
N06AX17 - Milnacipran	11 (0.2)	51.58 [25.74 ; 92.28]	66.19 [32.85 ; 116.80]
N06AB08 - Fluvoxamine	5 (0.1)	117.94 [38.21 ; 275.27]	78.72 [25.55 ; 182.50]

CHU

Hôpitaux de **Bordeaux** Inserm

Adera

Taking into account the extrapolation of patient number for the reference population in the EGB database between 2010 and 2014



N05CF01 - Zopiclone

N05CD06 - Lormetazepan

N05CX - Hypnotics and sedatives in combination

N05CD11 - Loprazolam

N05CD04 - Estazolam

N05CD03 - Flunitrazepan N05CD07 - Temazepam

N06A - Antidepressants

N06AB10 - Escitalopram

N06AX16 - Venlafaxine

N06AA09 - Amitriptyline

N06AB05 - Paroxetine

N06AB03 - Fluoxetine

N06AX03 - Mianserin

N06AB04 - Citalopram

N06AX21 - Duloxetine

N06AB06 - Sertraline

N06AX11 - Mirtazapine

N06AX14 - Tianeptine

AD).

Some extreme values were observed, none of them were unexpected (as flunitrazepam or agomelatine).

> 35th ICPE International Society for Pharmacoepidemiology August 24-28, 2019, Philadelphia, PA, USA [Abstract # 6386]



2.31 [2.12 - 2.52] 2.12 **[1.81 - 2.50]** 1.74 **[1.47 - 2.05]**

 3.13
 [2.58 - 3.81]

 2.80
 [2.25 - 3.50]

1.51 [1.21 - 1.89] 2.15 [1.64 - 2.82]

2.13 [1.54 - 2.97 3.25 [2.17 - 4.86

4.09 [2.63 - 6.36] 2.06 [1.25 - 3.39] 3.93 [1.78 - 8.65

1.61 [0.79 - 3.29

1.82 [0.84 - 3.92] 1.48 [0.67 - 3.26]

1.76 [0.70 - 4.48]

2.24 [2.00 - 2.50] 2.13 [1.83 - 2.49]

2.58 [1.92 - 3.48]

2.17 [1.37 - 3.73]

1.79 [0.99 - 3.22]

2.08 [0.73 - 5.91]

2.29 [2.08 - 2.51]

1.79 [1.47 - 2.18]

1.89 [1.52 - 2.34]

2.11 [1.67 - 2.67

2.47 [1.87 - 3.26]

2.61 [1.93 - 3.53] 2.59 [1.91 - 3.51]

2.04 [1.47 - 2.84] 2.90 [2.04 - 4.12]

2.04 [1.36 - 3.07] 2.35 [1.51 - 3.66]

 1.94
 [1.25 - 3.01]

 2.04
 [1.29 - 3.22]

 6.36
 [2.89 - 14.00]

 3.44
 [1.60 - 7.41]

4.17 [1.27 - 13.60]

7.50 [1.25 - 44.80]

 7.50
 [1.25 - 44.80]

 5.00
 [1.01 - 24.70]

2.07

[1.71 - 2.49]

407

131

44

42

12

1809

388

314 237

153

126

126

126

85

81 62

73

11

163

67

19

733

137

117

99

75

65

64 51

49

11